» Articles » PMID: 32284917

Molecular Subtype Discordance in a Young Woman with Synchronous Bilateral Breast Cancer: A Case Report

Overview
Journal Cureus
Date 2020 Apr 15
PMID 32284917
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Molecular subtype discordance in bilateral synchronous breast cancer is a relatively uncommon entity that poses unique therapeutic challenges. Here we report the case of a 35-year-old woman who presented to our clinic with synchronous bilateral breast cancer (SBBC), with stage IIA triple-negative disease in the right breast and a stage IIB hormone-sensitive tumor in the left breast. She was treated with bilateral modified radical mastectomy and axillary node dissection followed by adjuvant chemotherapy, radiotherapy, and a five-year regimen with daily tamoxifen. To date, the patient remains asymptomatic and free of disease recurrence 78 months after initiating treatment. Little is known about SBBC with a discordant molecular subtype and reports about this entity are scarce. Future studies aimed at identifying the optimal management strategy for this disease are needed.

Citing Articles

Whole‑exome sequencing insights into synchronous bilateral breast cancer with discordant molecular subtypes.

Hu S, Gao B, Li Z, Yuan Y Oncol Lett. 2024; 28(6):595.

PMID: 39430730 PMC: 11487496. DOI: 10.3892/ol.2024.14728.

References
1.
Hayashi M, Yamamoto Y, Takata N, Iwase H . A case of synchronous bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character. Springerplus. 2013; 2(1):272. PMC: 3696175. DOI: 10.1186/2193-1801-2-272. View

2.
Karsten M, Stempel M, Radosa J, Patil S, King T . Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer. Ann Surg Oncol. 2015; 23(2):471-6. PMC: 4720549. DOI: 10.1245/s10434-015-4841-4. View

3.
Copur M, Ramaekers R, Gauchan D, Crockett D, Clark D . Synchronous Bilateral Breast Cancer With Discordant Histology. Oncology (Williston Park). 2017; 31(4):274-7, 312. View

4.
Garrison Jr L, Babigumira J, Masaquel A, Wang B, Lalla D, Brammer M . The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer. Value Health. 2015; 18(4):541-6. DOI: 10.1016/j.jval.2015.01.012. View

5.
Sighoko D, Liu J, Hou N, Gustafson P, Huo D . Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?. Oncologist. 2014; 19(6):592-601. PMC: 4041672. DOI: 10.1634/theoncologist.2013-0427. View